Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1296590 | 1.00 | TSHR (0.30) | TSHRCYP2C19 | |
| SCHEMBL30722302 | 1.00 | TSHR (0.30) | TSHRCYP2C19 | |
| SCHEMBL29859441 | 0.96 | TSHR (0.35) | TSHRCYP2C19 | |
| SCHEMBL5401146 | 0.96 | — | — | |
| SCHEMBL4413431 | 0.96 | — | — | |
| SCHEMBL20027402 | 0.72 | TSHR (0.35) | TSHRCYP2C19 | |
| SCHEMBL13182148 | 0.72 | — | — | |
| SCHEMBL21903317 | 0.72 | TSHR (0.35) | TSHRCYP2C19 | |
| SCHEMBL11038684 | 0.72 | — | — | |
| SCHEMBL6419760 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608730-B2 | Process for the preparation of an anti-tumor platinum (II)—complex | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2009-10-27 | — | — | US | disclosed |
| US-20080207935-A1 | Process for the Preparation of an Anti-Tumor Platinum (II) - Complex | DABUR RESEARCH FOUNDATION (IN) | 2008-08-28 | — | — | US | disclosed |
| EP-1749015-A1 | A PROCESS FOR THE PREPARATION OF AN ANTI-TUMOR PLATINUM(II)-COMPLEX | DABUR PHARMA LTD. (IN) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005075489-A1 | A PROCESS FOR THE PERPARATION OF AN ANTI-TUMOR PLATINUM (II) - COMPLEX | DABUR PHARMA LIMITED (IN) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207935-A1 | Process for the Preparation of an Anti-Tumor Platinum (II) - Complex | CLIC4, DDX41, DDX3X | TSHR 94/4885CYP2C19 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.